Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K. Gopal, Gilles Salles, Nathan Fowler et al.|Journal of Clinical Oncology|2018Cited by 103